Serial Number 88137748
Registration 5933531
700

Registration Progress

Application Filed
Sep 30, 2018
Under Examination
Apr 2, 2019
Approved for Publication
Feb 5, 2019
Published for Opposition
Feb 5, 2019
Registered
Dec 10, 2019

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2019-12-10)
Due: Dec 10, 2025 149 days

Trademark Image

Basic Information

Serial Number
88137748
Registration Number
5933531
Filing Date
September 30, 2018
Registration Date
December 10, 2019
Published for Opposition
February 5, 2019
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 10, 2019
Registration
Registered
Classes
005

Rights Holder

Allogene Therapeutics, Inc.

03
Address
210 E. Grand Avenue
South San Francisco, CA 94080

Ownership History

Allogene Therapeutics, Inc.

Original Applicant
03
South San Francisco, CA

Allogene Therapeutics, Inc.

Owner at Publication
03
South San Francisco, CA

Allogene Therapeutics, Inc.

Original Registrant
03
South San Francisco, CA

Legal Representation

Attorney
Colleen Ganin

USPTO Deadlines

Next Deadline
149 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2019-12-10)
Due Date
December 10, 2025
Grace Period Ends
June 10, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

31 events
Date Code Type Description
Feb 28, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 28, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 28, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 28, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 28, 2025 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 28, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 10, 2024 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 10, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER
Nov 7, 2019 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 6, 2019 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 26, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 25, 2019 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Oct 25, 2019 EX2G S SOU EXTENSION 2 GRANTED
Oct 25, 2019 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 22, 2019 EISU I TEAS STATEMENT OF USE RECEIVED
Oct 22, 2019 IUAF S USE AMENDMENT FILED
Oct 22, 2019 EXT2 S SOU EXTENSION 2 FILED
Oct 22, 2019 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 4, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 2, 2019 EXT1 S SOU EXTENSION 1 FILED
Oct 2, 2019 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 2, 2019 EX1G S SOU EXTENSION 1 GRANTED
Apr 2, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 5, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 5, 2019 PUBO A PUBLISHED FOR OPPOSITION
Jan 16, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 1, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 26, 2018 DOCK D ASSIGNED TO EXAMINER
Oct 9, 2018 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Oct 8, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 3, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy
First Use Anywhere: Feb 26, 2019
First Use in Commerce: Feb 26, 2019

Additional Information

Design Mark
The mark consists of a dotted circle design.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005

USPTO Documents

Loading USPTO documents...